The United Kingdom and the United States have announced a landmark bilateral deal that will maintain no levies on UK drug shipments being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise expenditure on drugs through the public health system. This move ensures that tariffs on these vital exports will be held at zero for a duration of 36 months.
This agreement follows previous statements to hike tariffs on branded drug imports, with figures discussed as high as one hundred percent.
"This agreement between the United Kingdom bolsters the global environment for new treatments and introduces long-overdue fairness to U.S.–U.K. drug exports," an announcement said.
Trade Importance
Pharmaceuticals constitute one of the Britain's biggest goods shipped to the US, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months leading up to the third quarter, the UK exported medicines worth £11.1bn to the US. This amount accounted for a significant portion of all goods exports in that timeframe.
"This agreement protects work, boosts investment and paves the way for the UK to establish itself as a worldwide center for medical research," a minister commented.
Key UK Commitments
The agreement entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it judges new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to raise overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments were more than 20%.
Broader Context
The deal takes place against a ongoing tension between the sector and the British authorities over medicine costs and regulatory access.
These tensions were heightened by claims that US consumers were charged several times more for the equivalent treatments than people in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward American operations.
One official publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
